Amgen said the expansion would bring 150 construction jobs to the area.
Al Seib / Los Angeles Times via Getty Images
Merry Christmas, Dublin, Ireland! On Tuesday, Amgen announced its plans to invest $100 million to build a new vial filling line at its Dublin plant.
Amgen, based in Thousand Oaks, California, manufactures, markets and distributes more than 25 drugs in the United States, and its operations are primarily located within the U.S. This latest expansion will be one of its largest outside North America. The project will add state-of-the-art technology and new site infrastructure to the existing Dun Laoghaire manufacturing plant.
Amgen said the expansion would bring 150 construction jobs to the area. The project has already begun and the people in these roles will be responsible for hitting Amgen’s target of making the new site fully operational by 2024.
The Amgen plant, a 37,000 square meter aseptic manufacturing facility, has been in Dun Laoghaire for ten years and currently operates with 670 staff. The manufacturing plant specializes in formulation, aseptic drug product filling, lyophilization, packaging and analytical testing using on-site laboratories.
The expansion will support the growing demand for Amgen medicines. “The investment we are announcing today will enable us to serve more patients here in Ireland and all over the world,” said Paul Greene, vice president of regional manufacturing at Amgen. “Since we acquired the manufacturing plant in Dun Laoghaire, we have now invested $900 million to expand and update our production facilities and to bring in new products and capabilities. This investment is a testament to our commitment to our local community and our highly skilled workforce.”
Leo Eric Varadkar, an Irish Fine Gael politician serving as Tánaiste and Minister for Enterprise, Trade and Employment, welcomed the new development at Amgen Dun Laoghaire.
“This $100m investment will bring the company’s total investment in the Dublin plant to $900m. Amgen is one of the world’s leading biotechnology companies, and this investment underscores Ireland’s position as a leading global location for the sector,” Varadkar said.
Martin Shanahan, CEO of IDA Ireland, said the investment confirms Amgen’s ongoing commitment to Ireland and is a further endorsement by a global leader in Ireland’s biopharmaceutical ecosystem.
Amgen has owned the manufacturing facility in Dún Laoghaire since 2011. Since then, the company has invested a total of $900 million USD in expansion dollars, helping to ensure the continuity of medicine supply as it expands internationally.
Amgen’s total revenues in 2020 exceeded $25 billion, and it is one of the 30 companies that comprise the Dow Jones Industrial Average.
Amgen has nearly 25,000 employees on a global scale, including more than 14,000 in the U.S., with offices in California, Florida, Kentucky, Massachusetts, Puerto Rico, and Rhode Island.
Featured Jobs on BioSpace
